Bulletin of Problems Biology and Medicine, Journal Year: 2024, Volume and Issue: 1(4), P. 433 - 433
Published: Jan. 1, 2024
Language: Английский
European Journal of Wood and Wood Products, Journal Year: 2025, Volume and Issue: 83(2)
Published: Feb. 19, 2025
Language: Английский
Citations
1
Nutrients, Journal Year: 2025, Volume and Issue: 17(5), P. 922 - 922
Published: March 6, 2025
Background: Alzheimer's disease (AD) represents one of the major challenges modern medicine, with a growing impact on public health and healthcare systems. In recent years, dietary supplements use has been subject increasing interest as complementary strategy for prevention treatment disease. Materials Methods: A Review reviews was conducted following PRISMA guidelines REAPPRAISED checklist to evaluate efficacy safety supplement in AD. The search, performed across scientific databases, identified 54 relevant articles, including 53 mini-review, after applying specific inclusion criteria removing duplicates. Results: body evidence suggests that some may help reduce cognitive decline, inflammation, target mechanisms behind However, many these are still under investigation, mixed results highlighting need high-quality research. key challenge is lack data optimal dosages, administration duration, long-term safety, which limits clinical guidelines. Some studies have reported positive effects from regimens, such curcumin (800 mg/day), omega-3 fatty acids (2 g/day), resveratrol (600 mg/day). Other supplements, like phosphatidylserine (300 multinutrient formulations, probiotics, vitamin E (2000 IU/day), melatonin (3-10 also show benefits, though study variability makes conclusions uncertain. Conclusions: While certain potential mitigating decline AD, inconsistent findings gaps dosage highlight rigorous, large-scale trials. Future research should focus personalized, multimodal strategies integrating targeted supplementation, patterns, microbiota-gut-brain interactions enhanced neuroprotection.
Language: Английский
Citations
1
Inflammopharmacology, Journal Year: 2025, Volume and Issue: unknown
Published: March 9, 2025
Abstract Parkinson's disease (PD) is characterized by motor impairment, glial-mediated inflammation, redox imbalance, and α-synuclein (α-syn) aggregation. Conventional therapies relieve early PD symptoms, but they do not repair dopaminergic neurons. Berberine (BBR) caffeine (CAF), both natural alkaloids, exhibited neuroprotective effects in many neurodegenerative disorders. Consequently, we hypothesized that the combination of BBR CAF would offer protection against PD-related impairments rotenone (ROT)-induced rat model when compared to commercial drug, metformin (MTF). Our results showed combined administration (25 mg/kg/day) (2.5 for four weeks prevented deficits, weight reduction, dopamine (DA) depletion, monoamine oxidase (MAO) activity ROT-induced rats comparison with monotherapy along MTF. This produced a notable effect reducing tumor necrosis factor (TNF)-α interleukin-16 (IL-6) midbrain rats. combinations markedly normalized tyrosine hydroxylase (TH) levels decreased total α-syn α-syn-p ser129 aggregation increased protein phosphatase 2A (PP2A) levels. Histological analysis indicated damaged neurons significant amelioration co-administration CAF. The molecular docking had binding affinity pocket surrounding α-syn, PP2A, TH They are predicted serve as effective inhibitors enzyme-mediated phosphorylation α-syn- pser129 . Conclusively, presents novel strategy neuroprotection blocking initial events incidence, demonstrating considerable anti-oxidative anti-inflammatory benefits relative Graphical abstract
Language: Английский
Citations
0
Bulletin of Problems Biology and Medicine, Journal Year: 2025, Volume and Issue: 1(1), P. 251 - 251
Published: Jan. 1, 2025
Language: Английский
Citations
0
Bulletin of Problems Biology and Medicine, Journal Year: 2024, Volume and Issue: 1(4), P. 433 - 433
Published: Jan. 1, 2024
Language: Английский
Citations
1